Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3% - Here's Why

Key Points

• Crescent Biopharma shares jumped 8.3% to about $19.58 on Monday, trading on much lighter volume (71,788 shares, down ~68% vs. average), after renewed analyst attention and price‑target updates.
• Wall Street sentiment is broadly positive with a consensus Buy rating and a $28 average price target, while some firms (Piper Sandler, Guggenheim) have set targets as high as $35.
• The company beat quarterly estimates with EPS of ($0.70) and revenue of $1.04M, though it still faces a projected full‑year loss (~-3.33 EPS); its lead asset is CPB‑201, a bifunctional PD‑L1/TGF‑β therapy, and institutional investors own roughly 75% of the stock.

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) traded up 8.3% on Monday . The stock traded as high as $19.33 and last traded at $19.5750. 71,788 shares changed hands during trading, a decline of 68% from the average session volume of 223,639 shares. The stock had previously closed at $18.07.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CBIO. Stifel Nicolaus set a $29.00 target price on Crescent Biopharma in a report on Thursday, February 26th. HC Wainwright lowered their price target on Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, March 2nd. Weiss Ratings lowered Crescent Biopharma from a "sell (e+)" rating to a "sell (e)" rating in a research report on Wednesday. Piper Sandler started coverage on Crescent Biopharma in a research report on Wednesday, January 28th. They set an "overweight" rating and a $35.00 price objective for the company. Finally, Guggenheim began coverage on Crescent Biopharma in a research note on Wednesday, January 21st. They set a "buy" rating and a $35.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Crescent Biopharma has a consensus rating of "Buy" and a consensus price target of $28.00.

Crescent Biopharma Stock Performance

The business's 50 day simple moving average is $16.15 and its 200-day simple moving average is $13.59. The company has a market cap of $493.88 million, a price-to-earnings ratio of -1.64 and a beta of 1.21.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.15. The company had revenue of $1.04 million during the quarter, compared to analyst estimates of $0.36 million. Research analysts expect that Crescent Biopharma, Inc. will post -3.33 earnings per share for the current year.

Institutional Investors Weigh In On Crescent Biopharma

Several institutional investors have recently made changes to their positions in the company. BVF Inc. IL grew its stake in shares of Crescent Biopharma by 98.1% in the 4th quarter. BVF Inc. IL now owns 2,748,763 shares of the biopharmaceutical company's stock valued at $32,600,000 after buying an additional 1,360,900 shares in the last quarter. Fcpm Iii Services B.V. bought a new position in Crescent Biopharma during the fourth quarter valued at approximately $19,899,000. Vestal Point Capital LP acquired a new stake in Crescent Biopharma in the fourth quarter valued at approximately $17,790,000. Opaleye Management Inc. acquired a new stake in Crescent Biopharma in the fourth quarter valued at approximately $13,975,000. Finally, Tang Capital Management LLC grew its position in Crescent Biopharma by 28.3% in the fourth quarter. Tang Capital Management LLC now owns 872,398 shares of the biopharmaceutical company's stock worth $10,347,000 after acquiring an additional 192,574 shares in the last quarter. 75.19% of the stock is currently owned by institutional investors and hedge funds.

About Crescent Biopharma

Crescent Biopharma, Inc NASDAQ: CBIO is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company's research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company's lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.